After what happened, who is going to be the 'greater fool' to buy from you???
This company doesn't make money, its only in phase 2....we will talk AFTER it passes phase 3, 80% biotechs never get through phase 3, price seem too expensive now for a company that is just starting phase 2....there are plenty phase 2 companies I know that trades less than $2.
Mgmt never had the intention to protect shareholders.....they are more into pocketing money. Need capital???Well, sell more shares to fund the company and their salaries - damn the dilution.....Share price now tanking below $1 and get de-listed??? Well, do an unannounced R/S that was vaguely voted on 3 months ago with no time table - damn be the shareholders.
With mgmt. like that, who would buy your stock? Believe me ZLCS is getting a bad rap now, and no smart investor or institutional is going to put their money into it. The only way your hopes of making a fortune is to pump of its potential....like 5-6 years down the line....let's see results first....by 5-6 years, I am not sure this stock will still be worth what it is now. GL bagholders.
another idiot, I was just stating the facts,$4.88 maintains the the uptrend from July 31, if you bought the spikes then you need to decide to buy hold or sell,, but for now there is no technical damage done here and I expect the trendline to continue until results are announced
There was nothing vague about the Zalicus R/S process, it was a very transparent process form beginning to end, and Zack's analyst Jason Napodano, even told us the approximate PPS management was shooting for, ~6 post-split. So, your accusation about the reverse split are baseless. Each point you have made is incorrect. Furthermore, reverse splits are mathematically neutral, and institutional investors ignore grade school preconceptions about a mythical 100 PPS ceiling (Priceline). As for your hypothesis that a phase 2 success is not substantial, I direct you to abiraterone as a case study, among many other very substantial and extremely successful phase 2's. Equity financing with funds such as Lincoln are SOP. This is why Zalicus has attended countless fund meetings, which they posted as news by the way. You say that Zalicus is not making money, yet their cHTS revenue continues to grow with extraordinary success and scientific breakthroughs (Sci Transl Med 19 June 2013: Vol. 5, Issue 190, p. 190ra79) and recently Amgen and Novartis published a patent together using Chalice. In addition, the Exalgo 32 mg is also a revenue stream. Exalgo is not only bringing in cash but an example of management's ability to get regulatory approval of an opioid, one of the most challenging classes to receive approval for. Zalicus is also expanding into sodium channel blockers. Finally, do not forget FOV1101 on the phase 2 Sanofi pipeline. Sanofi maintains this candidate with interest in moving it forward.